Androgen receptor

Last updated

AR
2AM9.png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases AR , AIS, AR8, DHTR, HUMARA, HYSP1, KD, NR3C4, SBMA, SMAX1, TFM, androgen receptor
External IDs OMIM: 313700; MGI: 88064; HomoloGene: 28; GeneCards: AR; OMA:AR - orthologs
Orthologs
SpeciesHumanMouse
Entrez

367

11835

Ensembl

ENSG00000169083

ENSMUSG00000046532

UniProt

P10275
Q9NUA2

P19091

RefSeq (mRNA)

NM_001011645
NM_000044
NM_001348061
NM_001348063
NM_001348064

NM_013476

RefSeq (protein)

NP_038504

Location (UCSC) Chr X: 67.54 – 67.73 Mb Chr X: 97.19 – 97.37 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse
Androgen_recep
PDB 1xow EBI.jpg
crystal structure of the human androgen receptor ligand binding domain bound with an androgen receptor nh2-terminal peptide, ar20-30, and r1881
Identifiers
SymbolAndrogen_recep
Pfam PF02166
InterPro IPR001103
Available protein structures:
Pfam   structures / ECOD  
PDB RCSB PDB; PDBe; PDBj
PDBsum structure summary
Normal function of the androgen receptor. Testosterone (T) enters the cell and, if 5-alpha-reductase is present, is converted into dihydrotestosterone (DHT). Upon steroid binding, the androgen receptor (AR) undergoes a conformational change and releases heat-shock proteins (hsps). Phosphorylation (P) occurs before or after steroid binding. The AR translocates to the nucleus where dimerization, DNA binding, and the recruitment of coactivators occur. Target genes are transcribed (mRNA) and translated into proteins. Human androgen receptor and androgen binding.svg
Normal function of the androgen receptor. Testosterone (T) enters the cell and, if 5-alpha-reductase is present, is converted into dihydrotestosterone (DHT). Upon steroid binding, the androgen receptor (AR) undergoes a conformational change and releases heat-shock proteins (hsps). Phosphorylation (P) occurs before or after steroid binding. The AR translocates to the nucleus where dimerization, DNA binding, and the recruitment of coactivators occur. Target genes are transcribed (mRNA) and translated into proteins.

The androgen receptor (AR), also known as NR3C4 (nuclear receptor subfamily 3, group C, member 4), is a type of nuclear receptor [9] that is activated by binding any of the androgenic hormones, including testosterone and dihydrotestosterone, [10] in the cytoplasm and then translocating into the nucleus. The androgen receptor is most closely related to the progesterone receptor, and progestins in higher dosages can block the androgen receptor. [11] [12]

The main function of the androgen receptor is as a DNA-binding transcription factor that regulates gene expression; [13] however, the androgen receptor has other functions as well. [14] Androgen-regulated genes are critical for the development and maintenance of the male sexual phenotype.

Function

Effect on development

In some cell types, testosterone interacts directly with androgen receptors, whereas, in others, testosterone is converted by 5-alpha-reductase to dihydrotestosterone, an even more potent agonist for androgen receptor activation. [15] Testosterone appears to be the primary androgen receptor-activating hormone in the Wolffian duct, whereas dihydrotestosterone is the main androgenic hormone in the urogenital sinus, urogenital tubercle, and hair follicles. [16] Testosterone is therefore responsible primarily for the development of male primary sexual characteristics, whilst dihydrotestosterone is responsible for secondary male characteristics.

Androgens cause slow maturation of the bones, but more of the potent maturation effect comes from the estrogen produced by aromatization of androgens. Steroid users of teen age may find that their growth had been stunted by androgen and/or estrogen excess. People with too little sex hormones can be short during puberty but end up taller as adults as in androgen insensitivity syndrome or estrogen insensitivity syndrome. [17]

Knockout-mice studies have shown that the androgen receptor is essential for normal female fertility, being required for development and full functionality of the ovarian follicles and ovulation, working through both intra-ovarian and neuroendocrine mechanisms. [18]

Maintenance of male skeletal integrity

Via the androgen receptor, androgens play a key role in the maintenance of male skeletal integrity. The regulation of this integrity by androgen receptor (AR) signaling can be attributed to both osteoblasts and osteocytes. [19]

Role in females

The AR plays a role in regulating female sexual, somatic, and behavioral functions. Experimental data using AR knockout female mice, provides evidence that the promotion of cardiac growth, kidney hypertrophy, cortical bone growth and regulation of trabecular bone structure is a result of DNA-binding-dependent actions of the AR in females.

Moreover, the importance of understanding female androgen receptors lies in their role in several genetic disorders including androgen insensitivity syndrome (AIS). Complete (CAIS) and partial (PAIS) which are a result of mutations in the genes that code for AR. These mutations cause the inactivation of AR due to mutations conferring resistance to circulating testosterone, with more than 400 different AR mutations reported.[ citation needed ]

Mechanism of action

Genomic

The primary mechanism of action for androgen receptors is direct regulation of gene transcription.

Androgens (also called androgenic hormones), such as testosterone or dihydrotestosterone, are understood to exert their primary effects through binding to an androgen receptor in the cytosol. The receptor is translocated to the nucleus upon androgen binding and ultimately results in the transcriptional regulation of a number of genes via androgen responsive elements. [20] This androgen response mechanism is perhaps best known and characterized in the context of male sexual differentiation and puberty, but plays a role in a variety of tissue types and processes. [21] [22] Upon binding to androgens, the androgen receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen-responsive genes. [23]

The binding of an androgen to the androgen receptor results in a conformational change in the receptor that, in turn, causes dissociation of heat shock proteins, transport from the cytosol into the cell nucleus, and dimerization. The androgen receptor dimer binds to a specific sequence of DNA known as a hormone response element, where it forms macromolacular protein condensates that might facilitate rapid gene regulation as consequence of local high protein concentrations together with other coregulators. [24] Androgen receptors interact with other proteins in the nucleus, resulting in up- or down-regulation of specific gene transcription. [25] Up-regulation or activation of transcription results in increased synthesis of messenger RNA, which, in turn, is translated by ribosomes to produce specific proteins. One of the known target genes of androgen receptor activation is the insulin-like growth factor 1 receptor (IGF-1R). [26] Thus, changes in levels of specific proteins in cells is one way that androgen receptors control cell behavior.

One function of androgen receptor that is independent of direct binding to its target DNA sequence is facilitated by recruitment via other DNA-binding proteins. One example is serum response factor, a protein that activates several genes that cause muscle growth. [27]

Androgen receptor is modified by post-translational modification through acetylation, [28] which directly promotes AR-mediated transactivation, apoptosis [29] and contact-independent growth of prostate cancer cells. [30] AR acetylation is induced by androgens [31] and determines recruitment into chromatin. [32] The AR acetylation site is a key target of NAD-dependent and TSA-dependent histone deacetylases [33] and long non-coding RNA. [34]

Non-genomic

More recently, androgen receptors have been shown to have a second mode of action. As has been also found for other steroid hormone receptors such as estrogen receptors, androgen receptors can have actions that are independent of their interactions with DNA. [14] [35] Androgen receptors interact with certain signal transduction proteins in the cytoplasm. Androgen binding to cytoplasmic androgen receptors can cause rapid changes in cell function independent of changes in gene transcription, such as changes in ion transport. Regulation of signal transduction pathways by cytoplasmic androgen receptors can indirectly lead to changes in gene transcription, for example, by leading to phosphorylation of other transcription factors.

Genetics

Gene

In humans, the androgen receptor is encoded by the AR gene located on the X chromosome at Xq11–12. [36] [37]

Deficiencies

At least 165 disease-causing mutations in this gene have been discovered. [38] The androgen insensitivity syndrome, formerly known as testicular feminization, is caused by a mutation in the androgen receptor gene on the X chromosome (locus: Xq11–Xq12). [39] The androgen receptor seems to affect neuron physiology and is defective in Kennedy's disease. [40] [41] In addition, point mutations and trinucleotide repeat polymorphisms have been linked to a number of additional disorders. [42]

CAG repeats

The AR gene contains CAG repeats that affect receptor function, where fewer repeats leads to increased receptor sensitivity to circulating androgens and more repeats leads to decreased receptor sensitivity. Studies have shown that racial variation in CAG repeats exists, [43] [44] with African-Americans having fewer repeats than non-Hispanic white Americans. [43] The racial trends in CAG repeats parallels the incidence and mortality of prostate cancer in these two groups.

Mutations

The enhancer and the gene encoding for these receptors contain recurrent mutations, such as structural rearrangements and copy number changes, acquired in the progression of metastatic castration-resistant prostate cancer (mCRPC) treatment with therapy targeting these receptors (abiraterone, enzalutamide), make the disease progression determined by the androgen receptor genotype. [45]

Structure

Structural domains of the two isoforms (AR-A and AR-B) of the human androgen receptor. Numbers above the bars refer to the amino acid residues that separate the domains starting from the N-terminus (left) to C-terminus (right). NTD = N-terminal domain, DBD = DNA-binding domain, LBD = ligand-binding domain, AF = activation function. Androgen receptor sequence.png
Structural domains of the two isoforms (AR-A and AR-B) of the human androgen receptor. Numbers above the bars refer to the amino acid residues that separate the domains starting from the N-terminus (left) to C-terminus (right). NTD = N-terminal domain, DBD = DNA-binding domain, LBD = ligand-binding domain, AF = activation function.

Isoforms

Two isoforms of the androgen receptor (A and B) have been identified: [46]

Domains

Like other nuclear receptors, the androgen receptor is modular in structure and is composed of the following functional domains labeled A through F: [48]

Splice variants

AR-V7 is an androgen receptor splice variant that can be detected in circulating tumor cells of metastatic prostate cancer patients [63] [64] and is predictive of resistance to some drugs. [65]

Clinical significance

High expression in androgen receptor has been linked to aggression and sex drive by affecting the HPA and HPG axis [66]

Aberrant androgen receptor coregulator activity may contribute to the progression of prostate cancer. [67] [45]

Ligands

Affinities [lower-alpha 1] [68]
Compound RBA Tooltip Relative binding affinity [lower-alpha 2]
Metribolone 100
Dihydrotestosterone 85
Cyproterone acetate 7.8
Bicalutamide 1.4
Nilutamide 0.9
Hydroxyflutamide 0.57
Flutamide <0.0057
Notes:
  1. ↑ At androgen receptors; measured in human prostate tissue.
  2. ↑ Relative to Metribolone, which is by definition 100%

Agonists

Mixed

Antagonists

As a drug target

The AR is an important therapeutic target in prostate cancer. Thus many different antiandrogens have been developed, primarily targeting the ligand-binding domain of the protein. [70] AR ligands can either be classified based on their structure (steroidal or nonsteroidal) or based on their ability to activate or inhibit transcription (agonists or antagonists). [71] Inhibitors that target alternative functional domains (N-terminal domain, DNA-binding domain) of the protein are still under development. [69]

Drug resistance

Alteration of ARs may lead to treatment resistance (castration resistance) in prostate cancer as there may be missense mutations of the ligand binding domain, amplifications of the gene coding for this receptor or in its enhancer, mostly, suggesting the presence of different subclones with different genotypes of these receptors. [45]

Interactions

Androgen receptor has been shown to interact with:

See also

Related Research Articles

<span class="mw-page-title-main">Glucocorticoid receptor</span> Receptor to which cortisol and other glucocorticoids bind

The glucocorticoid receptor also known as NR3C1 is the receptor to which cortisol and other glucocorticoids bind.

<span class="mw-page-title-main">PELP-1</span> Mammalian protein found in Homo sapiens

Proline-, glutamic acid- and leucine-rich protein 1 (PELP1) also known as modulator of non-genomic activity of estrogen receptor (MNAR) and transcription factor HMX3 is a protein that in humans is encoded by the PELP1 gene. is a transcriptional corepressor for nuclear receptors such as glucocorticoid receptors and a coactivator for estrogen receptors.

<span class="mw-page-title-main">Estrogen receptor alpha</span> Protein-coding gene in the species Homo sapiens

Estrogen receptor alpha (ERα), also known as NR3A1, is one of two main types of estrogen receptor, a nuclear receptor that is activated by the sex hormone estrogen. In humans, ERα is encoded by the gene ESR1.

<span class="mw-page-title-main">Transcription factor Jun</span> Mammalian protein found in Homo sapiens

Transcription factor Jun is a protein that in humans is encoded by the JUN gene. c-Jun, in combination with protein c-Fos, forms the AP-1 early response transcription factor. It was first identified as the Fos-binding protein p39 and only later rediscovered as the product of the JUN gene. c-jun was the first oncogenic transcription factor discovered. The proto-oncogene c-Jun is the cellular homolog of the viral oncoprotein v-jun. The viral homolog v-jun was discovered in avian sarcoma virus 17 and was named for ju-nana, the Japanese word for 17. The human JUN encodes a protein that is highly similar to the viral protein, which interacts directly with specific target DNA sequences to regulate gene expression. This gene is intronless and is mapped to 1p32-p31, a chromosomal region involved in both translocations and deletions in human malignancies.

<span class="mw-page-title-main">Nuclear receptor coactivator 1</span> Protein-coding gene in the species Homo sapiens

The nuclear receptor coactivator 1 (NCOA1), also called steroid receptor coactivator-1 (SRC-1), is a transcriptional coregulatory protein that contains several nuclear receptor–interacting domains and possesses intrinsic histone acetyltransferase activity. It is encoded by the gene NCOA1.

<span class="mw-page-title-main">Nuclear receptor coactivator 3</span> Protein found in humans

The nuclear receptor coactivator 3 also known as NCOA3 is a protein that, in humans, is encoded by the NCOA3 gene. NCOA3 is also frequently called 'amplified in breast 1' (AIB1), steroid receptor coactivator-3 (SRC-3), or thyroid hormone receptor activator molecule 1 (TRAM-1).

<span class="mw-page-title-main">Small heterodimer partner</span> Protein found in humans

The small heterodimer partner (SHP) also known as NR0B2 is a protein that in humans is encoded by the NR0B2 gene. SHP is a member of the nuclear receptor family of intracellular transcription factors. SHP is unusual for a nuclear receptor in that it lacks a DNA binding domain. Therefore, it is technically neither a transcription factor nor nuclear receptor but nevertheless it is still classified as such due to relatively high sequence homology with other nuclear receptor family members.

<span class="mw-page-title-main">RELA</span> Protein-coding gene in the species Homo sapiens

Transcription factor p65 also known as nuclear factor NF-kappa-B p65 subunit is a protein that in humans is encoded by the RELA gene.

<span class="mw-page-title-main">RAR-related orphan receptor alpha</span> Protein-coding gene in the species Homo sapiens

RAR-related orphan receptor alpha (RORα), also known as NR1F1 is a nuclear receptor that in humans is encoded by the RORA gene. RORα participates in the transcriptional regulation of some genes involved in circadian rhythm. In mice, RORα is essential for development of cerebellum through direct regulation of genes expressed in Purkinje cells. It also plays an essential role in the development of type 2 innate lymphoid cells (ILC2) and mutant animals are ILC2 deficient. In addition, although present in normal numbers, the ILC3 and Th17 cells from RORα deficient mice are defective for cytokine production.

<span class="mw-page-title-main">Transforming protein RhoA</span> Protein and coding gene in humans

Transforming protein RhoA, also known as Ras homolog family member A (RhoA), is a small GTPase protein in the Rho family of GTPases that in humans is encoded by the RHOA gene. While the effects of RhoA activity are not all well known, it is primarily associated with cytoskeleton regulation, mostly actin stress fibers formation and actomyosin contractility. It acts upon several effectors. Among them, ROCK1 and DIAPH1 are the best described. RhoA, and the other Rho GTPases, are part of a larger family of related proteins known as the Ras superfamily, a family of proteins involved in the regulation and timing of cell division. RhoA is one of the oldest Rho GTPases, with homologues present in the genomes since 1.5 billion years. As a consequence, RhoA is somehow involved in many cellular processes which emerged throughout evolution. RhoA specifically is regarded as a prominent regulatory factor in other functions such as the regulation of cytoskeletal dynamics, transcription, cell cycle progression and cell transformation.

<span class="mw-page-title-main">Retinoic acid receptor alpha</span> Protein found in humans

Retinoic acid receptor alpha (RAR-α), also known as NR1B1, is a nuclear receptor that in humans is encoded by the RARA gene.

<span class="mw-page-title-main">TGFB1I1</span> Protein-coding gene in the species Homo sapiens

Transforming growth factor beta-1-induced transcript 1 protein is a protein that in humans is encoded by the TGFB1I1 gene. Often put together with and studied alongside TGFB1I1 is the mouse homologue HIC-5. As the name suggests, TGFB1I1 is an induced form of the larger family of TGFB1. Studies suggest TGFB1I1 plays a role in processes of cell growth, proliferation, migration, differentiation and senescence. TGFB1I1 is most localized at focal adhesion complexes of cells, although it may be found active in the cytosol, nucleus and cell membrane as well.

<span class="mw-page-title-main">FHL2</span> Protein-coding gene in the species Homo sapiens

Four and a half LIM domains protein 2 also known as FHL-2 is a protein that in humans is encoded by the FHL2 gene. LIM proteins contain a highly conserved double zinc finger motif called the LIM domain.

<span class="mw-page-title-main">Non-POU domain-containing octamer-binding protein</span> Protein-coding gene in the species Homo sapiens

Non-POU domain-containing octamer-binding protein (NonO) is a protein that in humans is encoded by the NONO gene.

<span class="mw-page-title-main">NCOA4</span> Protein-coding gene in the species Homo sapiens

Nuclear receptor coactivator 4, also known as Androgen Receptor Activator (ARA70), is a protein that in humans is encoded by the NCOA4 gene. It plays an important role in ferritinophagy, acting as a cargo receptor, binding to the ferritin heavy chain and latching on to ATG8 on the surface of the autophagosome.

<span class="mw-page-title-main">Testicular receptor 2</span> Human protein-coding gene

The testicular receptor 2 (TR2) also known as NR2C1 is protein that in humans is encoded by the NR2C1 gene. TR2 is a member of the nuclear receptor family of transcription factors.

<span class="mw-page-title-main">SRA1</span> Protein-coding gene in the species Homo sapiens

Steroid receptor RNA activator 1 also known as steroid receptor RNA activator protein (SRAP) is a protein that in humans is encoded by the SRA1 gene. The mRNA transcribed from the SRA1 gene is a component of the ribonucleoprotein complex containing NCOA1. This functional RNA also encodes a protein.

<span class="mw-page-title-main">RNF14</span> Protein-coding gene in the species Homo sapiens

E3 ubiquitin-protein ligase RNF14 is an enzyme that in humans is encoded by the RNF14 gene.

<span class="mw-page-title-main">MAGEA11</span> Protein-coding gene in humans

Melanoma-associated antigen 11 is a protein that in humans is encoded by the MAGEA11 gene. It is also involved in the androgen and progesterone receptor signaling pathways.

EPI-001 is the first inhibitor of the androgen receptor amino-terminal domain. The single stereoisomer of EPI-001, EPI-002, is a first-in-class drug that the USAN council assigned a new stem class "-aniten" and the generic name "ralaniten". This distinguishes the anitens novel molecular mechanism from anti androgens that bind the C-terminus ligand-binding domain and have the stem class "lutamide". EPI-001 and its stereoisomers and analogues were discovered by Marianne Sadar and Raymond Andersen, who co-founded the pharmaceutical company ESSA Pharma Inc for the clinical development of anitens for the treatment of castration-resistant prostate cancer (CRPC).

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000169083 – Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000046532 – Ensembl, May 2017
  3. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ↑ Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS (June 1995). "Androgen receptor defects: historical, clinical, and molecular perspectives". Endocrine Reviews. 16 (3): 271–321. doi:10.1210/edrv-16-3-271. PMID   7671849.
  6. ↑ Gottlieb B, Lombroso R, Beitel LK, Trifiro MA (January 2005). "Molecular pathology of the androgen receptor in male (in)fertility". Reproductive Biomedicine Online. 10 (1): 42–8. doi:10.1016/S1472-6483(10)60802-4. PMID   15705293.
  7. ↑ Choong CS, Wilson EM (December 1998). "Trinucleotide repeats in the human androgen receptor: a molecular basis for disease". Journal of Molecular Endocrinology. 21 (3): 235–57. doi: 10.1677/jme.0.0210235 . PMID   9845666.
  8. ↑ Meehan KL, Sadar MD (May 2003). "Androgens and androgen receptor in prostate and ovarian malignancies". Frontiers in Bioscience. 8 (1–3): d780–800. doi: 10.2741/1063 . PMID   12700055.
  9. ↑ Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, et al. (December 2006). "International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors". Pharmacological Reviews. 58 (4): 782–97. doi:10.1124/pr.58.4.9. PMID   17132855. S2CID   28626145.
  10. ↑ Roy AK, Lavrovsky Y, Song CS, Chen S, Jung MH, Velu NK, et al. (1999). Regulation of androgen action. Vitamins & Hormones. Vol. 55. Elsevier. pp. 309–52. doi:10.1016/S0083-6729(08)60938-3. ISBN   978-0-12-709855-5. PMID   9949684.
  11. ↑ Bardin CW, Brown T, Isomaa VV, Jänne OA (1983). "Progestins can mimic, inhibit and potentiate the actions of androgens". Pharmacology & Therapeutics. 23 (3): 443–59. doi:10.1016/0163-7258(83)90023-2. PMID   6371845.
  12. ↑ Raudrant D, Rabe T (2003). "Progestogens with antiandrogenic properties". Drugs. 63 (5): 463–92. doi:10.2165/00003495-200363050-00003. PMID   12600226. S2CID   28436828.
  13. ↑ Mooradian AD, Morley JE, Korenman SG (February 1987). "Biological actions of androgens". Endocrine Reviews. 8 (1): 1–28. doi:10.1210/edrv-8-1-1. PMID   3549275.
  14. 1 2 Heinlein CA, Chang C (October 2002). "The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions". Molecular Endocrinology. 16 (10): 2181–7. doi: 10.1210/me.2002-0070 . PMID   12351684.
  15. ↑ Davison SL, Bell R (April 2006). "Androgen physiology". Seminars in Reproductive Medicine. 24 (2): 71–7. doi:10.1055/s-2006-939565. PMID   16633980. S2CID   260321076.
  16. ↑ Sinisi AA, Pasquali D, Notaro A, Bellastella A (2003). "Sexual differentiation". Journal of Endocrinological Investigation . 26 (3 Suppl): 23–28. PMID   12834017.
  17. ↑ Frank GR (September 2003). "Role of estrogen and androgen in pubertal skeletal physiology". Medical and Pediatric Oncology. 41 (3): 217–21. doi:10.1002/mpo.10340. PMID   12868122.
  18. ↑ Walters KA, Simanainen U, Handelsman DJ (March 2010). "Molecular insights into androgen actions in male and female reproductive function from androgen receptor knockout models". Human Reproduction Update. 16 (5): 543–58. doi: 10.1093/humupd/dmq003 . PMID   20231167.
  19. ↑ Sinnesael M, Claessens F, Laurent M, Dubois V, Boonen S, Deboel L, et al. (December 2012). "Androgen receptor (AR) in osteocytes is important for the maintenance of male skeletal integrity: evidence from targeted AR disruption in mouse osteocytes". Journal of Bone and Mineral Research. 27 (12): 2535–43. doi: 10.1002/jbmr.1713 . PMID   22836391.
  20. ↑ Gelmann EP (July 2002). "Molecular biology of the androgen receptor". Journal of Clinical Oncology. 20 (13): 3001–3015. doi:10.1200/JCO.2002.10.018. PMID   12089231.
  21. ↑ Li J, Al-Azzawi F (June 2009). "Mechanism of androgen receptor action". Maturitas. 63 (2): 142–148. doi:10.1016/j.maturitas.2009.03.008. PMID   19372015.
  22. ↑ Masiutin M, Yadav M (2023). "Alternative androgen pathways". WikiJournal of Medicine. 10: X. doi: 10.15347/WJM/2023.003 . S2CID   257943362.
  23. ↑ Coffey K, Robson CN (November 2012). "Regulation of the androgen receptor by post-translational modifications". The Journal of Endocrinology. 215 (2): 221–237. doi: 10.1530/JOE-12-0238 . PMID   22872761. S2CID   20933176.
  24. ↑ Yavuz S, Kabbech H (October 2023). "Compartmentalization of androgen receptors at endogenous genes in living cells". Nucleic Acids Research. 51 (20): 10992–11009. doi:10.1093/nar/gkad803. PMC   10639085 . PMID   37791849.
  25. ↑ Heemers HV, Tindall DJ (December 2007). "Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex". Endocrine Reviews. 28 (7): 778–808. doi: 10.1210/er.2007-0019 . PMID   17940184.
  26. ↑ Pandini G, Mineo R, Frasca F, Roberts CT, Marcelli M, Vigneri R, et al. (March 2005). "Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells". Cancer Research. 65 (5): 1849–57. doi: 10.1158/0008-5472.CAN-04-1837 . PMID   15753383.
  27. ↑ Vlahopoulos S, Zimmer WE, Jenster G, Belaguli NS, Balk SP, Brinkmann AO, et al. (March 2005). "Recruitment of the androgen receptor via serum response factor facilitates expression of a myogenic gene". The Journal of Biological Chemistry. 280 (9): 7786–92. doi: 10.1074/jbc.M413992200 . PMID   15623502.
  28. ↑ Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, et al. (July 2000). "p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation". The Journal of Biological Chemistry. 275 (27): 20853–60. doi: 10.1074/jbc.M000660200 . PMID   10779504.
  29. ↑ Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, et al. (May 2002). "Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function". Molecular and Cellular Biology. 22 (10): 3373–88. doi:10.1128/mcb.22.10.3373-3388.2002. PMC   133781 . PMID   11971970.
  30. ↑ Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D, et al. (December 2003). "Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth". Molecular and Cellular Biology. 23 (23): 8563–75. doi:10.1128/mcb.23.23.8563-8575.2003. PMC   262657 . PMID   14612401.
  31. ↑ Gong J, Zhu J, Goodman OB, Pestell RG, Schlegel PN, Nanus DM, et al. (March 2006). "Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells". Oncogene. 25 (14): 2011–21. doi: 10.1038/sj.onc.1209231 . PMID   16434977.
  32. ↑ Fu M, Rao M, Wu K, Wang C, Zhang X, Hessien M, et al. (July 2004). "The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity". The Journal of Biological Chemistry. 279 (28): 29436–49. doi: 10.1074/jbc.M313466200 . PMID   15123687.
  33. 1 2 Fu M, Liu M, Sauve AA, Jiao X, Zhang X, Wu X, et al. (November 2006). "Hormonal control of androgen receptor function through SIRT1". Molecular and Cellular Biology. 26 (21): 8122–35. doi:10.1128/MCB.00289-06. PMC   1636736 . PMID   16923962.
  34. ↑ Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, et al. (August 2013). "lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs". Nature. 500 (7464): 598–602. Bibcode:2013Natur.500..598Y. doi:10.1038/nature12451. PMC   4034386 . PMID   23945587.
  35. ↑ Fix C, Jordan C, Cano P, Walker WH (July 2004). "Testosterone activates mitogen-activated protein kinase and the cAMP response element binding protein transcription factor in Sertoli cells". Proceedings of the National Academy of Sciences of the United States of America. 101 (30): 10919–24. Bibcode:2004PNAS..10110919F. doi: 10.1073/pnas.0404278101 . PMC   503720 . PMID   15263086.
  36. ↑ Chang CS, Kokontis J, Liao ST (April 1988). "Molecular cloning of human and rat complementary DNA encoding androgen receptors". Science. 240 (4850): 324–6. Bibcode:1988Sci...240..324C. doi:10.1126/science.3353726. PMID   3353726.
  37. ↑ Trapman J, Klaassen P, Kuiper GG, van der Korput JA, Faber PW, van Rooij HC, et al. (May 1988). "Cloning, structure and expression of a cDNA encoding the human androgen receptor". Biochemical and Biophysical Research Communications. 153 (1): 241–8. doi:10.1016/S0006-291X(88)81214-2. PMID   3377788.
  38. ↑ Šimčíková D, Heneberg P (December 2019). "Refinement of evolutionary medicine predictions based on clinical evidence for the manifestations of Mendelian diseases". Scientific Reports. 9 (1): 18577. Bibcode:2019NatSR...918577S. doi:10.1038/s41598-019-54976-4. PMC   6901466 . PMID   31819097.
  39. ↑ Brown TR (1995). "Human androgen insensitivity syndrome". Journal of Andrology. 16 (4): 299–303. doi: 10.1002/j.1939-4640.1995.tb00533.x . PMID   8537246. S2CID   25940392.
  40. ↑ Kennedy WR, Alter M, Sung JH (July 1968). "Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait". Neurology. 18 (7): 671–80. doi:10.1212/WNL.18.7.671. PMID   4233749. S2CID   45735233.
  41. ↑ Yu Z, Dadgar N, Albertelli M, Gruis K, Jordan C, Robins DM, et al. (October 2006). "Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model". The Journal of Clinical Investigation. 116 (10): 2663–72. doi:10.1172/JCI28773. PMC   1564432 . PMID   16981011.
  42. ↑ Rajender S, Singh L, Thangaraj K (March 2007). "Phenotypic heterogeneity of mutations in androgen receptor gene". Asian Journal of Andrology. 9 (2): 147–79. doi: 10.1111/j.1745-7262.2007.00250.x . PMID   17334586.
  43. 1 2 Sartor O, Zheng Q, Eastham JA (February 1999). "Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer". Urology. 53 (2): 378–80. doi:10.1016/s0090-4295(98)00481-6. PMID   9933058.
  44. ↑ Weintrob N, Eyal O, Slakman M, Segev Becker A, Israeli G, Kalter-Leibovici O, et al. (2018). "The effect of CAG repeats length on differences in hirsutism among healthy Israeli women of different ethnicities". PLOS ONE. 13 (3): e0195046. Bibcode:2018PLoSO..1395046W. doi: 10.1371/journal.pone.0195046 . PMC   5871002 . PMID   29584789.
  45. 1 2 3 Herberts C, Annala M, Sipola J, Ng SW, Chen XE, Nurminen A, et al. (August 2022). "Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer". Nature. 608 (7921): 199–208. Bibcode:2022Natur.608..199H. doi:10.1038/s41586-022-04975-9. PMID   35859180. S2CID   250730778.
  46. ↑ Wilson CM, McPhaul MJ (February 1994). "A and B forms of the androgen receptor are present in human genital skin fibroblasts". Proceedings of the National Academy of Sciences of the United States of America. 91 (4): 1234–8. Bibcode:1994PNAS...91.1234W. doi: 10.1073/pnas.91.4.1234 . PMC   43131 . PMID   8108393.
  47. ↑ Gregory CW, He B, Wilson EM (December 2001). "The putative androgen receptor-A form results from in vitro proteolysis". Journal of Molecular Endocrinology. 27 (3): 309–19. doi: 10.1677/jme.0.0270309 . PMID   11719283.
  48. ↑ Brinkmann AO, Klaasen P, Kuiper GG, van der Korput JA, Bolt J, de Boer W, et al. (1989). "Structure and function of the androgen receptor". Urological Research. 17 (2): 87–93. doi:10.1007/BF00262026. PMID   2734982. S2CID   19706366.
  49. ↑ Zhang F, Biswas M, Massah S, Lee J, Lingadahalli S, Wong S, et al. (January 2023). "Dynamic phase separation of the androgen receptor and its coactivators key to regulate gene expression". Nucleic Acids Research. 51 (1): 99–116. doi:10.1093/nar/gkac1158. PMC   9841400 . PMID   36535377.
  50. ↑ Jenster G, van der Korput HA, Trapman J, Brinkmann AO (March 1995). "Identification of two transcription activation units in the N-terminal domain of the human androgen receptor". The Journal of Biological Chemistry. 270 (13): 7341–7346. doi: 10.1074/jbc.270.13.7341 . hdl: 1765/8551 . PMID   7706276.
  51. ↑ Asangani I, Blair IA, Van Duyne G, Hilser VJ, Moiseenkova-Bell V, Plymate S, et al. (2021). "Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer". The Journal of Biological Chemistry. 296: 100240. doi: 10.1074/jbc.REV120.012411 . PMC   7949100 . PMID   33384381.
  52. ↑ Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma AA, et al. (July 2005). "The structural basis of androgen receptor activation: intramolecular and intermolecular amino-carboxy interactions". Proceedings of the National Academy of Sciences of the United States of America. 102 (28): 9802–9807. Bibcode:2005PNAS..102.9802S. doi: 10.1073/pnas.0408819102 . PMC   1168953 . PMID   15994236.
  53. ↑ Klokk TI, Kurys P, Elbi C, Nagaich AK, Hendarwanto A, Slagsvold T, et al. (March 2007). "Ligand-specific dynamics of the androgen receptor at its response element in living cells". Molecular and Cellular Biology. 27 (5): 1823–1843. doi:10.1128/MCB.01297-06. PMC   1820481 . PMID   17189428.
  54. ↑ van Royen ME, Cunha SM, Brink MC, Mattern KA, Nigg AL, Dubbink HJ, et al. (April 2007). "Compartmentalization of androgen receptor protein-protein interactions in living cells". The Journal of Cell Biology. 177 (1): 63–72. doi:10.1083/jcb.200609178. PMC   2064112 . PMID   17420290.
  55. ↑ Langley E, Zhou ZX, Wilson EM (December 1995). "Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer". The Journal of Biological Chemistry. 270 (50): 29983–29990. doi: 10.1074/jbc.270.50.29983 . PMID   8530400.
  56. ↑ Berrevoets CA, Doesburg P, Steketee K, Trapman J, Brinkmann AO (August 1998). "Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2)". Molecular Endocrinology. 12 (8): 1172–1183. doi: 10.1210/mend.12.8.0153 . hdl: 1765/8892 . PMID   9717843.
  57. 1 2 Dubbink HJ, Hersmus R, Verma CS, van der Korput HA, Berrevoets CA, van Tol J, et al. (September 2004). "Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor". Molecular Endocrinology. 18 (9): 2132–2150. doi: 10.1210/me.2003-0375 . PMID   15178743.
  58. ↑ Van-Duyne G, Blair IA, Sprenger C, Moiseenkova-Bell V, Plymate S, Penning TM (2023-01-01). Litwack G (ed.). "The androgen receptor". Vitamins and Hormones. Hormone Receptors: Structures and Functions. 123. Academic Press: 439–481. doi:10.1016/bs.vh.2023.01.001. ISBN   978-0-443-13455-5. PMID   37717994.
  59. 1 2 Callewaert L, Van Tilborgh N, Claessens F (January 2006). "Interplay between two hormone-independent activation domains in the androgen receptor". Cancer Research. 66 (1): 543–553. doi:10.1158/0008-5472.CAN-05-2389. PMID   16397271.
  60. ↑ Tan MH, Li J, Xu HE, Melcher K, Yong EL (January 2015). "Androgen receptor: structure, role in prostate cancer and drug discovery". Acta Pharmacologica Sinica. 36 (1): 3–23. doi:10.1038/aps.2014.18. PMC   4571323 . PMID   24909511.
  61. ↑ Kaku N, Matsuda K, Tsujimura A, Kawata M (August 2008). "Characterization of nuclear import of the domain-specific androgen receptor in association with the importin alpha/beta and Ran-guanosine 5'-triphosphate systems". Endocrinology. 149 (8): 3960–9. doi:10.1210/en.2008-0137. PMC   2488236 . PMID   18420738.
  62. ↑ Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, et al. (October 2003). "Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor". The Journal of Biological Chemistry. 278 (43): 41998–2005. doi: 10.1074/jbc.M302460200 . PMID   12923188.
  63. ↑ Silberstein JL, Taylor MN, Antonarakis ES (April 2016). "Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer". Current Urology Reports. 17 (4): 29. doi:10.1007/s11934-016-0584-4. PMC   4888068 . PMID   26902623.
  64. ↑ Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. (September 2014). "AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer". The New England Journal of Medicine. 371 (11): 1028–38. doi:10.1056/NEJMoa1315815. PMC   4201502 . PMID   25184630.
  65. ↑ "Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2016-02-27.
  66. ↑ Cunningham RL, Lumia AR, McGinnis MY (2012). "Androgen receptors, sex behavior, and aggression". Neuroendocrinology. 96 (2): 131–40. doi:10.1159/000337663. PMC   3474193 . PMID   22414851.
  67. ↑ Heinlein CA, Chang C (April 2002). "Androgen receptor (AR) coregulators: an overview". Endocrine Reviews. 23 (2): 175–200. doi: 10.1210/edrv.23.2.0460 . PMID   11943742.
  68. ↑ Ayub M, Levell MJ (August 1989). "The effect of ketoconazole related imidazole drugs and antiandrogens on [3H] R 1881 binding to the prostatic androgen receptor and [3H]5 alpha-dihydrotestosterone and [3H]cortisol binding to plasma proteins". J. Steroid Biochem. 33 (2): 251–5. doi:10.1016/0022-4731(89)90301-4. PMID   2788775.
  69. 1 2 Elshan ND, Rettig MB, Jung ME (22 November 2018). "Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain". Medicinal Research Reviews. 39 (3): 910–960. doi:10.1002/med.21548. PMC   6608750 . PMID   30565725.
  70. ↑ Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, et al. (August 2014). "Androgen receptor antagonists for prostate cancer therapy". Endocrine-Related Cancer. 21 (4): T105–18. doi: 10.1530/ERC-13-0545 . PMID   24639562.
  71. ↑ Gao W, Bohl CE, Dalton JT (September 2005). "Chemistry and structural biology of androgen receptor". Chemical Reviews. 105 (9): 3352–70. doi:10.1021/cr020456u. PMC   2096617 . PMID   16159155.
  72. 1 2 Lin HK, Yeh S, Kang HY, Chang C (June 2001). "Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor". Proceedings of the National Academy of Sciences of the United States of America. 98 (13): 7200–5. Bibcode:2001PNAS...98.7200L. doi: 10.1073/pnas.121173298 . PMC   34646 . PMID   11404460.
  73. ↑ Shatkina L, Mink S, Rogatsch H, Klocker H, Langer G, Nestl A, et al. (October 2003). "The cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-terminal region of the receptor". Molecular and Cellular Biology. 23 (20): 7189–97. doi:10.1128/MCB.23.20.7189-7197.2003. PMC   230325 . PMID   14517289.
  74. ↑ Knee DA, Froesch BA, Nuber U, Takayama S, Reed JC (April 2001). "Structure-function analysis of Bag1 proteins. Effects on androgen receptor transcriptional activity". The Journal of Biological Chemistry. 276 (16): 12718–24. doi: 10.1074/jbc.M010841200 . PMID   11278763.
  75. ↑ Froesch BA, Takayama S, Reed JC (May 1998). "BAG-1L protein enhances androgen receptor function". The Journal of Biological Chemistry. 273 (19): 11660–6. doi: 10.1074/jbc.273.19.11660 . PMID   9565586.
  76. 1 2 3 4 Song LN, Coghlan M, Gelmann EP (January 2004). "Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor". Molecular Endocrinology. 18 (1): 70–85. doi: 10.1210/me.2003-0189 . PMID   14593076.
  77. 1 2 3 Masiello D, Chen SY, Xu Y, Verhoeven MC, Choi E, Hollenberg AN, et al. (October 2004). "Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells". Molecular Endocrinology. 18 (10): 2388–401. doi: 10.1210/me.2003-0436 . PMID   15256534.
  78. ↑ Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, et al. (March 2002). "Linking beta-catenin to androgen-signaling pathway". The Journal of Biological Chemistry. 277 (13): 11336–44. doi: 10.1074/jbc.M111962200 . PMID   11792709.
  79. ↑ Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP (August 2003). "A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4". The Journal of Biological Chemistry. 278 (33): 30828–34. doi: 10.1074/jbc.M301208200 . PMID   12799378.
  80. ↑ Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC (August 2003). "Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis". Oncogene. 22 (36): 5602–13. doi: 10.1038/sj.onc.1206802 . PMID   12944908.
  81. ↑ Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM, et al. (June 2002). "Liganded androgen receptor interaction with beta-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells". The Journal of Biological Chemistry. 277 (23): 20702–10. doi: 10.1074/jbc.M200545200 . PMID   11916967.
  82. ↑ Park JJ, Irvine RA, Buchanan G, Koh SS, Park JM, Tilley WD, et al. (November 2000). "Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor". Cancer Research. 60 (21): 5946–9. PMID   11085509.
  83. ↑ Yeh S, Hu YC, Rahman M, Lin HK, Hsu CL, Ting HJ, et al. (October 2000). "Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells". Proceedings of the National Academy of Sciences of the United States of America. 97 (21): 11256–61. Bibcode:2000PNAS...9711256Y. doi: 10.1073/pnas.190353897 . PMC   17187 . PMID   11016951.
  84. ↑ Sato N, Sadar MD, Bruchovsky N, Saatcioglu F, Rennie PS, Sato S, et al. (July 1997). "Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between the androgen receptor and AP-1/c-Jun in the human prostate cancer cell line LNCaP". The Journal of Biological Chemistry. 272 (28): 17485–94. doi: 10.1074/jbc.272.28.17485 . PMID   9211894.
  85. ↑ Cifuentes E, Mataraza JM, Yoshida BA, Menon M, Sacks DB, Barrack ER, et al. (January 2004). "Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cells". Proceedings of the National Academy of Sciences of the United States of America. 101 (2): 464–9. Bibcode:2004PNAS..101..464C. doi: 10.1073/pnas.0307161101 . PMC   327170 . PMID   14695896.
  86. ↑ Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP (April 2001). "Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation". The Journal of Biological Chemistry. 276 (16): 13442–51. doi: 10.1074/jbc.M006598200 . PMID   11278309.
  87. ↑ Lee DK, Duan HO, Chang C (March 2001). "Androgen receptor interacts with the positive elongation factor P-TEFb and enhances the efficiency of transcriptional elongation". The Journal of Biological Chemistry. 276 (13): 9978–84. doi: 10.1074/jbc.M002285200 . PMID   11266437.
  88. ↑ Beauchemin AM, Gottlieb B, Beitel LK, Elhaji YA, Pinsky L, Trifiro MA (2001). "Cytochrome c oxidase subunit Vb interacts with human androgen receptor: a potential mechanism for neurotoxicity in spinobulbar muscular atrophy". Brain Research Bulletin. 56 (3–4): 285–97. doi:10.1016/S0361-9230(01)00583-4. PMID   11719263. S2CID   24740136.
  89. ↑ Kim J, Jia L, Stallcup MR, Coetzee GA (February 2005). "The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus". Journal of Molecular Endocrinology. 34 (1): 107–18. doi: 10.1677/jme.1.01701 . PMID   15691881.
  90. ↑ Frønsdal K, Engedal N, Slagsvold T, Saatcioglu F (November 1998). "CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1". The Journal of Biological Chemistry. 273 (48): 31853–9. doi: 10.1074/jbc.273.48.31853 . PMID   9822653.
  91. 1 2 3 Ishitani K, Yoshida T, Kitagawa H, Ohta H, Nozawa S, Kato S (July 2003). "p54nrb acts as a transcriptional coactivator for activation function 1 of the human androgen receptor". Biochemical and Biophysical Research Communications. 306 (3): 660–5. doi:10.1016/S0006-291X(03)01021-0. PMID   12810069.
  92. ↑ Aarnisalo P, Palvimo JJ, Jänne OA (March 1998). "CREB-binding protein in androgen receptor-mediated signaling". Proceedings of the National Academy of Sciences of the United States of America. 95 (5): 2122–7. Bibcode:1998PNAS...95.2122A. doi: 10.1073/pnas.95.5.2122 . PMC   19270 . PMID   9482849.
  93. ↑ Reutens AT, Watanabe G, Albanese C, McPhaul MJ, Balk SP, Pestell RG (1998). "Cyclin D1 binds activating mutants of the androgen receptor". US Endocrine Society Meeting (1–528).
  94. ↑ Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, et al. (May 2001). "Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner". Molecular Endocrinology. 15 (5): 797–811. doi: 10.1210/mend.15.5.0641 . PMID   11328859.
  95. ↑ Petre-Draviam CE, Williams EB, Burd CJ, Gladden A, Moghadam H, Meller J, et al. (January 2005). "A central domain of cyclin D1 mediates nuclear receptor corepressor activity". Oncogene. 24 (3): 431–44. doi: 10.1038/sj.onc.1208200 . PMID   15558026.
  96. ↑ Knudsen KE, Cavenee WK, Arden KC (May 1999). "D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability". Cancer Research. 59 (10): 2297–301. PMID   10344732.
  97. ↑ Lee DK, Duan HO, Chang C (March 2000). "From androgen receptor to the general transcription factor TFIIH. Identification of cdk activating kinase (CAK) as an androgen receptor NH(2)-terminal associated coactivator". The Journal of Biological Chemistry. 275 (13): 9308–13. doi: 10.1074/jbc.275.13.9308 . PMID   10734072.
  98. ↑ Wu K, Katiyar S, Witkiewicz A, Li A, McCue P, Song LN, et al. (April 2009). "The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth". Cancer Research. 69 (8): 3347–55. doi:10.1158/0008-5472.CAN-08-3821. PMC   2669850 . PMID   19351840.
  99. ↑ Lin DY, Fang HI, Ma AH, Huang YS, Pu YS, Jenster G, et al. (December 2004). "Negative modulation of androgen receptor transcriptional activity by Daxx". Molecular and Cellular Biology. 24 (24): 10529–41. doi:10.1128/MCB.24.24.10529-10541.2004. PMC   533990 . PMID   15572661.
  100. ↑ Wafa LA, Cheng H, Rao MA, Nelson CC, Cox M, Hirst M, et al. (October 2003). "Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system". The Biochemical Journal. 375 (Pt 2): 373–83. doi:10.1042/BJ20030689. PMC   1223690 . PMID   12864730.
  101. ↑ Niki T, Takahashi-Niki K, Taira T, Iguchi-Ariga SM, Ariga H (February 2003). "DJBP: a novel DJ-1-binding protein, negatively regulates the androgen receptor by recruiting histone deacetylase complex, and DJ-1 antagonizes this inhibition by abrogation of this complex". Molecular Cancer Research. 1 (4): 247–61. PMID   12612053.
  102. ↑ Bonaccorsi L, Carloni V, Muratori M, Formigli L, Zecchi S, Forti G, et al. (October 2004). "EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR)" (PDF). International Journal of Cancer. 112 (1): 78–86. doi:10.1002/ijc.20362. hdl: 2158/395766 . PMID   15305378. S2CID   46121331.
  103. ↑ Bonaccorsi L, Muratori M, Carloni V, Marchiani S, Formigli L, Forti G, et al. (August 2004). "The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells". Steroids. 69 (8–9): 549–52. doi:10.1016/j.steroids.2004.05.011. hdl: 2158/395763 . PMID   15288768. S2CID   23831527.
  104. ↑ Li P, Lee H, Guo S, Unterman TG, Jenster G, Bai W (January 2003). "AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR". Molecular and Cellular Biology. 23 (1): 104–18. doi:10.1128/MCB.23.1.104-118.2003. PMC   140652 . PMID   12482965.
  105. ↑ Koshy B, Matilla T, Burright EN, Merry DE, Fischbeck KH, Orr HT, et al. (September 1996). "Spinocerebellar ataxia type-1 and spinobulbar muscular atrophy gene products interact with glyceraldehyde-3-phosphate dehydrogenase". Human Molecular Genetics. 5 (9): 1311–8. doi: 10.1093/hmg/5.9.1311 . PMID   8872471.
  106. ↑ Nishimura K, Ting HJ, Harada Y, Tokizane T, Nonomura N, Kang HY, et al. (August 2003). "Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator". Cancer Research. 63 (16): 4888–94. PMID   12941811.
  107. ↑ Rigas AC, Ozanne DM, Neal DE, Robson CN (November 2003). "The scaffolding protein RACK1 interacts with androgen receptor and promotes cross-talk through a protein kinase C signaling pathway". The Journal of Biological Chemistry. 278 (46): 46087–93. doi: 10.1074/jbc.M306219200 . PMID   12958311.
  108. ↑ Wang L, Lin HK, Hu YC, Xie S, Yang L, Chang C (July 2004). "Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells". The Journal of Biological Chemistry. 279 (31): 32444–52. doi: 10.1074/jbc.M313963200 . PMID   15178691.
  109. 1 2 Gaughan L, Logan IR, Cook S, Neal DE, Robson CN (July 2002). "Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor". The Journal of Biological Chemistry. 277 (29): 25904–13. doi: 10.1074/jbc.M203423200 . PMID   11994312.
  110. ↑ Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E (March 1992). "Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation". Biochemistry. 31 (8): 2393–9. doi:10.1021/bi00123a026. PMID   1540595.
  111. ↑ Nemoto T, Ohara-Nemoto Y, Ota M (September 1992). "Association of the 90-kDa heat shock protein does not affect the ligand-binding ability of androgen receptor". The Journal of Steroid Biochemistry and Molecular Biology. 42 (8): 803–12. doi:10.1016/0960-0760(92)90088-Z. PMID   1525041. S2CID   24978960.
  112. 1 2 Bai S, He B, Wilson EM (February 2005). "Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction". Molecular and Cellular Biology. 25 (4): 1238–57. doi:10.1128/MCB.25.4.1238-1257.2005. PMC   548016 . PMID   15684378.
  113. ↑ Bai S, Wilson EM (March 2008). "Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor". Molecular and Cellular Biology. 28 (6): 1947–63. doi:10.1128/MCB.01672-07. PMC   2268407 . PMID   18212060.
  114. ↑ Wang Q, Sharma D, Ren Y, Fondell JD (November 2002). "A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression". The Journal of Biological Chemistry. 277 (45): 42852–8. doi: 10.1074/jbc.M206061200 . PMID   12218053.
  115. ↑ Sharma M, Zarnegar M, Li X, Lim B, Sun Z (November 2000). "Androgen receptor interacts with a novel MYST protein, HBO1". The Journal of Biological Chemistry. 275 (45): 35200–8. doi: 10.1074/jbc.M004838200 . PMID   10930412.
  116. ↑ Ueda T, Mawji NR, Bruchovsky N, Sadar MD (October 2002). "Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells". The Journal of Biological Chemistry. 277 (41): 38087–94. doi: 10.1074/jbc.M203313200 . PMID   12163482.
  117. ↑ Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG (December 1999). "The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1". Molecular and Cellular Biology. 19 (12): 8383–92. doi:10.1128/mcb.19.12.8383. PMC   84931 . PMID   10567563.
  118. 1 2 Wang Q, Udayakumar TS, Vasaitis TS, Brodie AM, Fondell JD (April 2004). "Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cells". The Journal of Biological Chemistry. 279 (17): 17319–28. doi: 10.1074/jbc.M400970200 . PMID   14966121.
  119. 1 2 3 He B, Wilson EM (March 2003). "Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs". Molecular and Cellular Biology. 23 (6): 2135–50. doi:10.1128/MCB.23.6.2135-2150.2003. PMC   149467 . PMID   12612084.
  120. ↑ Tan JA, Hall SH, Petrusz P, French FS (September 2000). "Thyroid receptor activator molecule, TRAM-1, is an androgen receptor coactivator". Endocrinology. 141 (9): 3440–50. doi: 10.1210/endo.141.9.7680 . PMID   10965917.
  121. ↑ Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN (December 2001). "Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer". British Journal of Cancer. 85 (12): 1928–36. doi:10.1054/bjoc.2001.2179. PMC   2364015 . PMID   11747336.
  122. 1 2 3 He B, Minges JT, Lee LW, Wilson EM (March 2002). "The FXXLF motif mediates androgen receptor-specific interactions with coregulators". The Journal of Biological Chemistry. 277 (12): 10226–35. doi: 10.1074/jbc.M111975200 . PMID   11779876.
  123. ↑ Alen P, Claessens F, Schoenmakers E, Swinnen JV, Verhoeven G, Rombauts W, et al. (January 1999). "Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1alpha with multiple steroid receptors and identification of an internally deleted ELE1beta isoform". Molecular Endocrinology. 13 (1): 117–28. doi: 10.1210/mend.13.1.0214 . PMID   9892017.
  124. ↑ Yeh S, Chang C (May 1996). "Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells". Proceedings of the National Academy of Sciences of the United States of America. 93 (11): 5517–21. Bibcode:1996PNAS...93.5517Y. doi: 10.1073/pnas.93.11.5517 . PMC   39278 . PMID   8643607.
  125. ↑ Miyamoto H, Yeh S, Wilding G, Chang C (June 1998). "Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells". Proceedings of the National Academy of Sciences of the United States of America. 95 (13): 7379–84. Bibcode:1998PNAS...95.7379M. doi: 10.1073/pnas.95.13.7379 . PMC   22623 . PMID   9636157.
  126. ↑ Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C (May 1999). "From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells". Proceedings of the National Academy of Sciences of the United States of America. 96 (10): 5458–63. Bibcode:1999PNAS...96.5458Y. doi: 10.1073/pnas.96.10.5458 . PMC   21881 . PMID   10318905.
  127. ↑ Zhou ZX, He B, Hall SH, Wilson EM, French FS (February 2002). "Domain interactions between coregulator ARA(70) and the androgen receptor (AR)". Molecular Endocrinology. 16 (2): 287–300. doi: 10.1210/mend.16.2.0765 . PMID   11818501.
  128. ↑ Gao T, Brantley K, Bolu E, McPhaul MJ (October 1999). "RFG (ARA70, ELE1) interacts with the human androgen receptor in a ligand-dependent fashion, but functions only weakly as a coactivator in cotransfection assays". Molecular Endocrinology. 13 (10): 1645–56. doi: 10.1210/mend.13.10.0352 . PMID   10517667.
  129. ↑ Goo YH, Na SY, Zhang H, Xu J, Hong S, Cheong J, et al. (February 2004). "Interactions between activating signal cointegrator-2 and the tumor suppressor retinoblastoma in androgen receptor transactivation". The Journal of Biological Chemistry. 279 (8): 7131–5. doi: 10.1074/jbc.M312563200 . PMID   14645241.
  130. ↑ Liao G, Chen LY, Zhang A, Godavarthy A, Xia F, Ghosh JC, et al. (February 2003). "Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT". The Journal of Biological Chemistry. 278 (7): 5052–61. doi: 10.1074/jbc.M206374200 . PMID   12441355.
  131. ↑ Dotzlaw H, Moehren U, Mink S, Cato AC, Iñiguez Lluhí JA, Baniahmad A (April 2002). "The amino terminus of the human AR is target for corepressor action and antihormone agonism". Molecular Endocrinology. 16 (4): 661–73. doi: 10.1210/mend.16.4.0798 . PMID   11923464.
  132. ↑ Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, et al. (July 2000). "p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation". The Journal of Biological Chemistry. 275 (27): 20853–60. doi: 10.1074/jbc.M000660200 . PMID   10779504.
  133. ↑ Zhang Y, Fondell JD, Wang Q, Xia X, Cheng A, Lu ML, et al. (August 2002). "Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1". Oncogene. 21 (36): 5609–18. doi: 10.1038/sj.onc.1205638 . PMID   12165860.
  134. ↑ Yang F, Li X, Sharma M, Zarnegar M, Lim B, Sun Z (May 2001). "Androgen receptor specifically interacts with a novel p21-activated kinase, PAK6". The Journal of Biological Chemistry. 276 (18): 15345–53. doi: 10.1074/jbc.M010311200 . PMID   11278661.
  135. ↑ Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML, et al. (January 2002). "AR and ER interaction with a p21-activated kinase (PAK6)". Molecular Endocrinology. 16 (1): 85–99. doi: 10.1210/mend.16.1.0753 . PMID   11773441.
  136. 1 2 Pero R, Lembo F, Palmieri EA, Vitiello C, Fedele M, Fusco A, et al. (February 2002). "PATZ attenuates the RNF4-mediated enhancement of androgen receptor-dependent transcription". The Journal of Biological Chemistry. 277 (5): 3280–5. doi: 10.1074/jbc.M109491200 . PMID   11719514.
  137. ↑ Kotaja N, Aittomäki S, Silvennoinen O, Palvimo JJ, Jänne OA (December 2000). "ARIP3 (androgen receptor-interacting protein 3) and other PIAS (protein inhibitor of activated STAT) proteins differ in their ability to modulate steroid receptor-dependent transcriptional activation". Molecular Endocrinology. 14 (12): 1986–2000. doi: 10.1210/mend.14.12.0569 . PMID   11117529.
  138. ↑ Moilanen AM, Karvonen U, Poukka H, Yan W, Toppari J, Jänne OA, et al. (February 1999). "A testis-specific androgen receptor coregulator that belongs to a novel family of nuclear proteins". The Journal of Biological Chemistry. 274 (6): 3700–4. doi: 10.1074/jbc.274.6.3700 . PMID   9920921.
  139. ↑ Zhao Y, Goto K, Saitoh M, Yanase T, Nomura M, Okabe T, et al. (August 2002). "Activation function-1 domain of androgen receptor contributes to the interaction between subnuclear splicing factor compartment and nuclear receptor compartment. Identification of the p102 U5 small nuclear ribonucleoprotein particle-binding protein as a coactivator for the receptor". The Journal of Biological Chemistry. 277 (33): 30031–9. doi: 10.1074/jbc.M203811200 . PMID   12039962.
  140. 1 2 Lin HK, Hu YC, Lee DK, Chang C (October 2004). "Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells". Molecular Endocrinology. 18 (10): 2409–23. doi: 10.1210/me.2004-0117 . PMID   15205473.
  141. ↑ Wang L, Hsu CL, Ni J, Wang PH, Yeh S, Keng P, et al. (March 2004). "Human checkpoint protein hRad9 functions as a negative coregulator to repress androgen receptor transactivation in prostate cancer cells". Molecular and Cellular Biology. 24 (5): 2202–13. doi:10.1128/MCB.24.5.2202-2213.2004. PMC   350564 . PMID   14966297.
  142. ↑ Rao MA, Cheng H, Quayle AN, Nishitani H, Nelson CC, Rennie PS (December 2002). "RanBPM, a nuclear protein that interacts with and regulates transcriptional activity of androgen receptor and glucocorticoid receptor". The Journal of Biological Chemistry. 277 (50): 48020–7. doi: 10.1074/jbc.M209741200 . PMID   12361945.
  143. ↑ Beitel LK, Elhaji YA, Lumbroso R, Wing SS, Panet-Raymond V, Gottlieb B, et al. (August 2002). "Cloning and characterization of an androgen receptor N-terminal-interacting protein with ubiquitin-protein ligase activity". Journal of Molecular Endocrinology. 29 (1): 41–60. doi: 10.1677/jme.0.0290041 . PMID   12200228.
  144. ↑ Lu J, Danielsen M (November 1998). "Differential regulation of androgen and glucocorticoid receptors by retinoblastoma protein". The Journal of Biological Chemistry. 273 (47): 31528–33. doi: 10.1074/jbc.273.47.31528 . PMID   9813067.
  145. ↑ Yeh S, Miyamoto H, Nishimura K, Kang H, Ludlow J, Hsiao P, et al. (July 1998). "Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells". Biochemical and Biophysical Research Communications. 248 (2): 361–7. doi: 10.1006/bbrc.1998.8974 . PMID   9675141.
  146. ↑ Miyamoto H, Rahman M, Takatera H, Kang HY, Yeh S, Chang HC, et al. (February 2002). "A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth". The Journal of Biological Chemistry. 277 (7): 4609–17. doi: 10.1074/jbc.M108312200 . PMID   11673464.
  147. ↑ Kang HY, Yeh S, Fujimoto N, Chang C (March 1999). "Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor". The Journal of Biological Chemistry. 274 (13): 8570–6. doi: 10.1074/jbc.274.13.8570 . PMID   10085091.
  148. ↑ Moilanen AM, Poukka H, Karvonen U, Häkli M, Jänne OA, Palvimo JJ (September 1998). "Identification of a novel RING finger protein as a coregulator in steroid receptor-mediated gene transcription". Molecular and Cellular Biology. 18 (9): 5128–39. doi:10.1128/mcb.18.9.5128. PMC   109098 . PMID   9710597.
  149. ↑ Poukka H, Aarnisalo P, Santti H, Jänne OA, Palvimo JJ (January 2000). "Coregulator small nuclear RING finger protein (SNURF) enhances Sp1- and steroid receptor-mediated transcription by different mechanisms". The Journal of Biological Chemistry. 275 (1): 571–9. doi: 10.1074/jbc.275.1.571 . PMID   10617653.
  150. ↑ Liu Y, Kim BO, Kao C, Jung C, Dalton JT, He JJ (May 2004). "Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activation". The Journal of Biological Chemistry. 279 (21): 21766–73. doi: 10.1074/jbc.M314321200 . PMID   15031286.
  151. ↑ Chipuk JE, Cornelius SC, Pultz NJ, Jorgensen JS, Bonham MJ, Kim SJ, et al. (January 2002). "The androgen receptor represses transforming growth factor-beta signaling through interaction with Smad3". The Journal of Biological Chemistry. 277 (2): 1240–8. doi: 10.1074/jbc.M108855200 . PMID   11707452.
  152. ↑ Hayes SA, Zarnegar M, Sharma M, Yang F, Peehl DM, ten Dijke P, et al. (March 2001). "SMAD3 represses androgen receptor-mediated transcription". Cancer Research. 61 (5): 2112–8. PMID   11280774.
  153. ↑ Kang HY, Huang KE, Chang SY, Ma WL, Lin WJ, Chang C (November 2002). "Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4". The Journal of Biological Chemistry. 277 (46): 43749–56. doi: 10.1074/jbc.M205603200 . PMID   12226080.
  154. ↑ Gobinet J, Auzou G, Nicolas JC, Sultan C, Jalaguier S (December 2001). "Characterization of the interaction between androgen receptor and a new transcriptional inhibitor, SHP". Biochemistry. 40 (50): 15369–77. doi:10.1021/bi011384o. PMID   11735420.
  155. ↑ Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, et al. (October 2004). "Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence". Cancer Research. 64 (19): 7156–68. doi: 10.1158/0008-5472.CAN-04-1121 . PMID   15466214.
  156. ↑ Powell SM, Christiaens V, Voulgaraki D, Waxman J, Claessens F, Bevan CL (March 2004). "Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate". Endocrine-Related Cancer. 11 (1): 117–30. doi: 10.1677/erc.0.0110117 . PMID   15027889.
  157. ↑ Yuan X, Lu ML, Li T, Balk SP (December 2001). "SRY interacts with and negatively regulates androgen receptor transcriptional activity". The Journal of Biological Chemistry. 276 (49): 46647–54. doi: 10.1074/jbc.M108404200 . PMID   11585838.
  158. ↑ Matsuda T, Junicho A, Yamamoto T, Kishi H, Korkmaz K, Saatcioglu F, et al. (April 2001). "Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells". Biochemical and Biophysical Research Communications. 283 (1): 179–87. doi:10.1006/bbrc.2001.4758. PMID   11322786.
  159. ↑ Ueda T, Bruchovsky N, Sadar MD (March 2002). "Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways". The Journal of Biological Chemistry. 277 (9): 7076–85. doi: 10.1074/jbc.M108255200 . PMID   11751884.
  160. ↑ Ting HJ, Yeh S, Nishimura K, Chang C (January 2002). "Supervillin associates with androgen receptor and modulates its transcriptional activity". Proceedings of the National Academy of Sciences of the United States of America. 99 (2): 661–6. Bibcode:2002PNAS...99..661T. doi: 10.1073/pnas.022469899 . PMC   117362 . PMID   11792840.
  161. ↑ Mu X, Chang C (October 2003). "TR2 orphan receptor functions as negative modulator for androgen receptor in prostate cancer cells PC-3". The Prostate. 57 (2): 129–33. doi:10.1002/pros.10282. PMID   12949936. S2CID   24134119.
  162. ↑ Lee YF, Shyr CR, Thin TH, Lin WJ, Chang C (December 1999). "Convergence of two repressors through heterodimer formation of androgen receptor and testicular orphan receptor-4: a unique signaling pathway in the steroid receptor superfamily". Proceedings of the National Academy of Sciences of the United States of America. 96 (26): 14724–9. Bibcode:1999PNAS...9614724L. doi: 10.1073/pnas.96.26.14724 . PMC   24715 . PMID   10611280.
  163. ↑ Wang X, Yang Y, Guo X, Sampson ER, Hsu CL, Tsai MY, et al. (May 2002). "Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator". The Journal of Biological Chemistry. 277 (18): 15426–31. doi: 10.1074/jbc.M111218200 . PMID   11856738.
  164. ↑ Hsiao PW, Chang C (August 1999). "Isolation and characterization of ARA160 as the first androgen receptor N-terminal-associated coactivator in human prostate cells". The Journal of Biological Chemistry. 274 (32): 22373–9. doi: 10.1074/jbc.274.32.22373 . PMID   10428808.
  165. ↑ Miyajima N, Maruyama S, Bohgaki M, Kano S, Shigemura M, Shinohara N, et al. (May 2008). "TRIM68 regulates ligand-dependent transcription of androgen receptor in prostate cancer cells". Cancer Research. 68 (9): 3486–94. doi: 10.1158/0008-5472.CAN-07-6059 . PMID   18451177.
  166. ↑ Poukka H, Aarnisalo P, Karvonen U, Palvimo JJ, Jänne OA (July 1999). "Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription". The Journal of Biological Chemistry. 274 (27): 19441–6. doi: 10.1074/jbc.274.27.19441 . PMID   10383460.
  167. ↑ Müller JM, Isele U, Metzger E, Rempel A, Moser M, Pscherer A, et al. (February 2000). "FHL2, a novel tissue-specific coactivator of the androgen receptor". The EMBO Journal. 19 (3): 359–69. doi:10.1093/emboj/19.3.359. PMC   305573 . PMID   10654935.
  168. ↑ Cheng S, Brzostek S, Lee SR, Hollenberg AN, Balk SP (July 2002). "Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor". Molecular Endocrinology. 16 (7): 1492–501. doi: 10.1210/mend.16.7.0870 . PMID   12089345.
  169. ↑ Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC, Choi E, et al. (February 2005). "The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists". The Journal of Biological Chemistry. 280 (8): 6511–9. doi: 10.1074/jbc.M408972200 . PMID   15598662.
  170. ↑ Markus SM, Taneja SS, Logan SK, Li W, Ha S, Hittelman AB, et al. (February 2002). "Identification and characterization of ART-27, a novel coactivator for the androgen receptor N terminus". Molecular Biology of the Cell. 13 (2): 670–82. doi:10.1091/mbc.01-10-0513. PMC   65658 . PMID   11854421.
  171. ↑ Sharma M, Li X, Wang Y, Zarnegar M, Huang CY, Palvimo JJ, et al. (November 2003). "hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci". The EMBO Journal. 22 (22): 6101–14. doi:10.1093/emboj/cdg585. PMC   275443 . PMID   14609956.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.